LSTANasdaqPharmaceutical PreparationsFiscal year ends December 31
LISATA THERAPEUTICS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$1.00−0.03 (-2.91%)
Close on Oct 19, 2026
- Market cap
- $9.11M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$1.44 (−59.02%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
LISATA THERAPEUTICS, INC. saw revenue fall 90.7% to $100.00K over the twelve months to Jun 30, 2026. Free cash flow was -$12.32M.
Revenue
$100.00K
-90.7% vs. a year earlier
Operating income
-$16.43M
TTM Q2 2026
Free cash flow
-$12.32M
TTM Q2 2026
EPS, diluted
-$1.65
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $9.11M
- P/E ratio
- –
- Price to sales
- 91.06
- Price to book
- 1.10
- Dividend yield
- –
- Free cash flow yield
- -135.33%
Fundamentals
- Revenue
- $100.00K
- Net income
- -$14.62M
- EPS, diluted
- -$1.65
- Free cash flow
- -$12.32M
- Book value per share
- $0.91
- Diluted shares
- 9M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
$100.00K-90.7% YoY
Gross profit
–
Operating income
-$16.43M
Net income
-$14.62M
EPS, diluted
-$1.65
Free cash flow
-$12.32M
Reported periodTrailing twelve months